Published online May 7, 2023. doi: 10.3748/wjg.v29.i17.2551
Peer-review started: December 26, 2022
First decision: March 8, 2023
Revised: March 10, 2023
Accepted: April 13, 2023
Article in press: April 13, 2023
Published online: May 7, 2023
Processing time: 132 Days and 0.9 Hours
Alcohol-related hepatitis (ARH) is a unique type of alcohol-associated liver disease characterized by acute liver inflammation caused by significant alcohol use. It ranges in severity from mild to severe and carries significant morbidity and mortality. The refinement of scoring systems has enhanced prognostication and guidance of clinical decision-making in the treatment of this complex disease. Although treatment focuses on supportive care, steroids have shown benefit in select circumstances. There has been a recent interest in this disease process, as coronavirus disease 2019 pandemic led to substantial rise in cases. Although much is known regarding the pathogenesis, prognosis remains grim due to limited treatment options. This article summarizes the epidemiology, genetics, pathogenesis, diagnosis and treatment of ARH.
Core Tip: The aim of this article is to review alcohol-related hepatitis (ARH). Despite the increased understanding of the pathogenesis of this disease process, treatment options remain limited. Our review article focuses on epidemiology, genetics, pathogenesis, diagnosis and treatment. We also discuss complications of ARH along with their optimal management and ongoing clinical trials. Further research evaluating therapeutic targets for its management are warranted.